阿斯利康/第一三共 Trop-2 ADC：临床策略、注册策略
占据印度的糖尿病和减肥药市场，并不是看上去那样两厢情愿”地一蹴而就。
Time：
2024-03-18 08:12
Author：
yangyi
Recommended content
WCLC 2026 | Hansun "Blows the Roof Off", the New King of B7-H3 ADC is About to be Crowned
It's time for Chinese innovative drugs to redefine the standards.
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务